Here, we present the synthesis and characterization of a new potentially nonadentate chelator, H4pypa and its bifunctional analog tBu4pypa-C7-NHS conjugated to PSMA (prostate-specific membrane antigen) - targeting peptidomimetic (Glu-urea-Lys). H4pypa is very functionally versatile and biologically stable. Compared to the conventional chelators (e.g. DOTA, DTPA), H4pypa has outstanding affinities for both 111In (EC, t1/2 ~2.8 d) and 177Lu (-, t1/2~6.64 d). Its radiolabeled complexes were achieved at >98% radiochemical yield, RT within 10 minutes, at ligand concentration as low as 10-6 M, with excellent stability in human serum over at least 5-7 days (<1% transchelation). The thermodynamic stabilities of the [M(pypa)]- complexes (M3+ = In3+, Lu3+, La3+) were dependent on the ionic radii, where the smaller In3+ has the highest pM value (30.5), followed by Lu3+ (22.6) and La3+ (19.9). All pM values are remarkably higher than those with DOTA, DTPA, H4octapa, H4octox and H4neunpa. Moreover, the facile and versatile bifunctionalization enabled by the p-OH group in the central pyridyl bridge of the pypa scaffold (compound 14) allows incorporation of a variety of linkers for bioconjugation through easy nucleophilic substitution. In this work, an alkyl linker was selected to couple H4pypa to a PSMA-targeting pharmacophore, proving that the bioconjugation sacrifices neither the tumor-targeting nor the chelation properties. The biodistribution profiles of 111In- and 177Lu-labeled tracers are different, but promising, with the 177Lu analog particularly outstanding.